The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today ...

CAR T-cell therapy has been hugely successful in treating certain types of tumours, and stiffening up cancer cells beforehand ...

A next-generation CAR T cell immunotherapy targeting the urokinase receptor has eliminated treatment-resistant glioblastoma tumours in preclinical models.

CAR-T cell therapy is already a potent treatment for certain cancers. Now, a small study is showing early promise for ...

T-cell therapy continues to reshape the treatment landscape for patients with relapsed or refractory large B-cell lymphoma (R ...

A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For patients whose disease returns after an allogeneic stem cell transplant, the ...

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...

Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...